UnitedHealth Group shares are moving lower as investors re-price regulatory and legal risk tied to federal scrutiny of Medicare Advantage billing and coding practices. That overhang is colliding with ongoing Medicare Advantage rate concerns after CMS proposed a near-flat 0.09% net payment increase for 2027—well below what the market had been positioned for—keeping sentiment fragile across managed-care names. (statnews.com)

The central fear is that heightened enforcement could translate into incremental compliance costs, repayment demands, or penalties, while also limiting coding-related revenue capture in Medicare Advantage. UnitedHealth has said it is cooperating with DOJ inquiries into its Medicare practices, but the existence of both civil and criminal scrutiny keeps a persistent discount on the shares as investors handicap worst-case scenarios. (unitedhealthgroup.com)

Even aside from legal headlines, Medicare Advantage economics remain under pressure. CMS’s proposed 2027 framework points to a 0.09% net payment change from 2026 to 2027 and includes policy proposals that can affect risk-score revenue, a key profit lever for large MA operators; investors are treating the proposal as a warning shot ahead of the final announcement due on or before April 6, 2026. (spglobal.com)

Near-term, traders will focus on any incremental legal or regulatory milestones tied to Medicare Advantage billing oversight, plus commentary from management on coding, audits, and compliance posture. On the policy side, the next major swing factor is whether CMS meaningfully revises the proposed 2027 Medicare Advantage rates and related risk-adjustment policies in the final April announcement, which will set the tone for 2027 bid season and forward earnings power.